Morgans Keeps Their Hold Rating on Telstra Corporation Limited (TTRAF)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Harris is a 2-star analyst with an average return of 1.3% and a 42.98% success rate. Harris covers the Technology sector, focusing on stocks such as Atturra Limited, Xero Limited, and Megaport.
In addition to Morgans, Telstra Corporation Limited also received a Hold from J.P. Morgan's Bob Chen CFA in a report issued today. However, on August 1, Jefferies maintained a Buy rating on Telstra Corporation Limited (Other OTC: TTRAF).
The company has a one-year high of $3.50 and a one-year low of $2.19. Currently, Telstra Corporation Limited has an average volume of 2,685.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Insider
10 hours ago
- Business Insider
Roku Stock (NASDAQ:ROKU) Dips as Howdy Installation Proves a Mite Aggressive
Remember just a couple of weeks ago when we first heard about the new Howdy streaming app from streaming video stock Roku (ROKU)? While some thought it was a fine idea, and others were not so certain, there are some signs that Howdy may be a bit more intrusive than anyone expected. And investors are not exactly pleased about this, sending shares down fractionally in the closing minutes of Thursday's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Basically, not long after Howdy officially launched, Roku put out the command to install it on not only Roku devices, but also on every Roku smart TV. Anything with the Roku branding on it got Howdy whether its owner wanted it or not. Of course, for some, this was just a handy shortcut to get an app they were likely going to get anyway to see what was on it. But for others, they never wanted Howdy around in the first place. Reports note, however, that removing Howdy is surprisingly easy, and about as simple. Just start at the home screen, find Howdy—usually, newer apps install near the bottom of the list—and then just use the star button on your remote to open up options. Select 'remove channel' from there, and just like that, Howdy moseys off into the sunset. Should you change your mind later, reinstalling Howdy will work like installing any other app. A Seat at the Sports Table We all know that sports are playing an ever-increasing role in the strategies of streaming platforms. And, as it turns out, Roku will have a seat at the table in talking about the future of sports. It will be joining representatives of several other platforms including FuboTV (FUBO) and Amazon's (AMZN) Prime Video at the upcoming TheGrill 2025 event. Roku will be part of a session titled 'Sports & Streaming: Driving Value Across the Ecosystem.' The session will cover topics like rights purchases, building content hubs, and technical innovation in the sector. The end result should be a lot of new information coming out that demonstrates where the future of sports streaming will be headed. And Roku's presence therein demonstrates that it has credibility enough to join in the proceedings. Is Roku Stock a Good Buy? Turning to Wall Street, analysts have a Moderate Buy consensus rating on ROKU stock based on 15 Buys, six Holds, and one Sell assigned in the past three months, as indicated by the graphic below. After a 48.62% rally in its share price over the past year, the average ROKU price target of $104.05 per share implies 18.91% upside potential.
Business Insider
11 hours ago
- Business Insider
Ord Minnett Remains a Sell on Westpac Banking (WEBNF)
In a report released today, from Ord Minnett maintained a Sell rating on Westpac Banking, with a price target of A$30.00. The company's shares closed yesterday at $23.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Ord Minnett, Westpac Banking also received a Sell from Morgans's Nathan Lead in a report issued today. However, yesterday, UBS maintained a Buy rating on Westpac Banking (Other OTC: WEBNF). The company has a one-year high of $23.28 and a one-year low of $16.30. Currently, Westpac Banking has an average volume of 3,277. Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WEBNF in relation to earlier this year.
